MAP4K4 Gene Silencing in Human Skeletal Muscle Prevents Tumor Necrosis Factor-α-induced Insulin Resistance
Tumor necrosis factor-α (TNF-α) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-α-induced negative regulation of extracellular...
Saved in:
Published in | The Journal of biological chemistry Vol. 282; no. 11; pp. 7783 - 7789 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
16.03.2007
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9258 1083-351X |
DOI | 10.1074/jbc.M608602200 |
Cover
Loading…
Abstract | Tumor necrosis factor-α (TNF-α) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-α-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-α-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-α-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-α. Depletion of MAP4K4 also prevented TNF-α-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-α-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-α-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake. |
---|---|
AbstractList | Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-alpha-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-alpha-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-alpha-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-alpha. Depletion of MAP4K4 also prevented TNF-alpha-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-alpha-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-alpha-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake.Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-alpha-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-alpha-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-alpha-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-alpha. Depletion of MAP4K4 also prevented TNF-alpha-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-alpha-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-alpha-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake. Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-alpha-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-alpha-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-alpha-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-alpha. Depletion of MAP4K4 also prevented TNF-alpha-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-alpha-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-alpha-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake. Tumor necrosis factor- alpha (TNF- alpha ) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF- alpha -induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH sub(2)-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF- alpha -induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF- alpha -induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF- alpha . Depletion of MAP4K4 also prevented TNF- alpha -induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF- alpha -treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF- alpha -induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake. Tumor necrosis factor-α (TNF-α) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested whether mitogenic-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) causes the TNF-α-induced negative regulation of extracellular signal-regulated kinase-1/2 (ERK-1/2), c-Jun NH2-terminal kinase (JNK), and the insulin receptor substrate-1 (IRS-1) on the insulin signaling pathway governing glucose metabolism. Using small interfering RNA (siRNA) to suppress the expression of MAP4K4 protein 85% in primary human skeletal muscle cells, we provide evidence that TNF-α-induced insulin resistance on glucose uptake was completely prevented. MAP4K4 silencing inhibited TNF-α-induced negative signaling inputs by preventing excessive JNK and ERK-1/2 phosphorylation, as well as IRS-1 serine phosphorylation. These results highlight the MAPK4K4/JNK/ERK/IRS module in the negative regulation of insulin signaling to glucose transport in response to TNF-α. Depletion of MAP4K4 also prevented TNF-α-induced insulin resistance on Akt and the Akt substrate 160 (AS160), providing evidence that appropriate insulin signaling inputs for glucose metabolism were rescued. Silencing of MAP2K1 and MAP2K4, signaling proteins downstream of MAP4K4, recapitulated the effect of MAP4K4 siRNA in TNF-α-treated cells. Thus, strategies to inhibit MAP4K4 may be efficacious in the prevention of TNF-α-induced inhibitory signals that cause skeletal muscle insulin resistance on glucose metabolism in humans. Moreover, in myotubes from insulin-resistant type II diabetic patients, siRNA against MAP4K4, MAP2K4, or MAP2K1 restored insulin action on glucose uptake to levels observed in healthy subjects. Collectively, our results demonstrate that MAP4K4 silencing prevents insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake. |
Author | Bouzakri, Karim Zierath, Juleen R. |
Author_xml | – sequence: 1 givenname: Karim surname: Bouzakri fullname: Bouzakri, Karim – sequence: 2 givenname: Juleen R. surname: Zierath fullname: Zierath, Juleen R. email: Juleen.Zierath@ki.se |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17227768$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:12133354$$DView record from Swedish Publication Index |
BookMark | eNqFkU1LXDEYhUOx1NG67bJk1d2dJrkfyV2K1A_qtKIW3IXc5J0S595kmg-lP6t_xN9kZKYWCmI2b8j7nEM4Zw_tOO8AoQ-UzCnhzefbQc8XHREdYYyQN2hGiairuqU3O2hGCKNVz1qxi_ZivCXlND19h3YpZ4zzTszQanF40Xxt8Ak4wFd2BKet-4mtw6d5Ug5frWCEpEa8yFGPgC8C3IFLEV_nyQf8DXTw0UZ8rHTyoXr4U1lnsgaDz1zMY_G5hLJPyml4j94u1RjhYDv30Y_jL9dHp9X595Ozo8PzSjctTZXWqhVs0B1ZDsKAqDtOhBn6XmjGGR9EJ4wgPaF8ORjQLde07etadarmojFdvY-qjW-8h3Ue5DrYSYXf0isrt0-rcgPZckYJLfynDb8O_leGmORko4ZxVA58jpIT1rIS3Ksg7UXTc1YX8OMWzMME5vkHf3MvQLMBnuKLAZZS26SS9S4FZUdJiXyqV5Z65b96i2z-n-zZ-SWB2Aig5H1nIciobekYjA2gkzTeviR9BIaZuhE |
CitedBy_id | crossref_primary_10_1016_j_jlr_2022_100238 crossref_primary_10_1186_s40246_020_00285_1 crossref_primary_10_1016_j_bbi_2008_08_006 crossref_primary_10_1124_jpet_124_002065 crossref_primary_10_1002_advs_202206814 crossref_primary_10_1021_acs_jmedchem_8b00152 crossref_primary_10_7570_kjo_2014_23_3_203 crossref_primary_10_3390_ani2020243 crossref_primary_10_1080_13813450903164330 crossref_primary_10_1016_j_tem_2008_11_004 crossref_primary_10_1126_sciadv_abi9654 crossref_primary_10_1016_j_ejcb_2011_06_004 crossref_primary_10_1002_1878_0261_12055 crossref_primary_10_1186_1471_2164_9_367 crossref_primary_10_1111_j_1748_1716_2010_02201_x crossref_primary_10_1194_jlr_M800402_JLR200 crossref_primary_10_1038_ncomms9995 crossref_primary_10_2337_db10_1178 crossref_primary_10_1007_s00125_011_2183_8 crossref_primary_10_1038_s41598_024_67648_9 crossref_primary_10_2337_db07_0763 crossref_primary_10_3390_antiox11112090 crossref_primary_10_1038_srep15197 crossref_primary_10_1152_ajpregu_00310_2010 crossref_primary_10_1590_1414_431x20165826 crossref_primary_10_1371_journal_pntd_0001740 crossref_primary_10_1615_CritRevImmunol_2024051277 crossref_primary_10_3389_fphys_2023_1148146 crossref_primary_10_1111_j_1467_789X_2011_00900_x crossref_primary_10_1152_ajpendo_90714_2008 crossref_primary_10_1038_nature07774 crossref_primary_10_1152_ajpendo_90667_2008 crossref_primary_10_1242_jeb_089920 crossref_primary_10_1007_s11695_019_03755_1 crossref_primary_10_1517_17460441_2010_504203 crossref_primary_10_2337_db16_0882 crossref_primary_10_28957_rcmfr_v27n2a2 crossref_primary_10_1021_acsmedchemlett_5b00215 crossref_primary_10_1021_jm500155b crossref_primary_10_1210_me_2014_1147 crossref_primary_10_1016_j_cellimm_2014_02_006 crossref_primary_10_1080_13813450802181047 crossref_primary_10_2337_db07_0583 crossref_primary_10_1016_j_tiv_2018_09_014 crossref_primary_10_31590_ejosat_746132 crossref_primary_10_1016_j_jep_2022_116091 crossref_primary_10_1021_cr5002832 crossref_primary_10_15407_fz60_02_045 crossref_primary_10_1016_j_celrep_2020_107860 crossref_primary_10_1016_j_numecd_2014_10_005 crossref_primary_10_1371_journal_ppat_1003737 crossref_primary_10_1152_ajpcell_00056_2021 crossref_primary_10_1016_j_celrep_2019_01_019 crossref_primary_10_1371_journal_pone_0083471 crossref_primary_10_1016_j_biopha_2018_02_012 crossref_primary_10_1038_nrm2391 crossref_primary_10_1186_1476_511X_9_42 crossref_primary_10_1074_jbc_M700665200 crossref_primary_10_1038_s42255_021_00470_z crossref_primary_10_1007_s00125_009_1330_y crossref_primary_10_1016_j_bbrep_2016_12_013 crossref_primary_10_1128_MCB_00618_12 crossref_primary_10_1016_j_bbi_2009_09_009 crossref_primary_10_1111_j_1748_1716_2007_01786_x crossref_primary_10_4093_kdj_2010_34_3_191 crossref_primary_10_1152_physiolgenomics_00024_2014 crossref_primary_10_1038_s41598_024_57000_6 crossref_primary_10_1152_physrev_90100_2007 crossref_primary_10_1016_j_diff_2024_100832 crossref_primary_10_1007_s00125_007_0834_6 crossref_primary_10_1016_j_jbiotec_2008_07_206 crossref_primary_10_1371_journal_pone_0020489 crossref_primary_10_1038_s41467_019_08287_x crossref_primary_10_1074_jbc_M112_362632 crossref_primary_10_2337_db11_1790 crossref_primary_10_1021_ci200153c crossref_primary_10_1152_ajpregu_00561_2007 crossref_primary_10_1016_j_celrep_2013_03_018 crossref_primary_10_1016_j_jfluchem_2011_12_006 crossref_primary_10_1016_S0895_3988_09_60019_2 crossref_primary_10_1016_j_intimp_2023_110841 crossref_primary_10_1038_cddis_2015_381 crossref_primary_10_1371_journal_pone_0093856 crossref_primary_10_1007_s00125_009_1465_x crossref_primary_10_1016_j_tem_2016_04_006 crossref_primary_10_1016_j_biomaterials_2013_01_079 crossref_primary_10_1113_EP091712 crossref_primary_10_1074_jbc_M109_048058 crossref_primary_10_1371_journal_ppat_1004003 crossref_primary_10_3389_fonc_2022_1059513 crossref_primary_10_1038_s41598_018_28117_2 crossref_primary_10_1111_j_1749_6632_2009_04984_x crossref_primary_10_1186_s13578_016_0121_7 crossref_primary_10_1097_MCO_0b013e32833aabd9 crossref_primary_10_1371_journal_pone_0077788 crossref_primary_10_1016_j_chembiol_2019_10_005 crossref_primary_10_1016_j_etap_2016_08_006 crossref_primary_10_1126_sciadv_ade0631 crossref_primary_10_1002_path_6248 crossref_primary_10_1016_j_phymed_2024_155382 crossref_primary_10_1016_j_molmet_2014_07_007 crossref_primary_10_1038_ncomms5602 crossref_primary_10_1158_1535_7163_MCT_13_0296 crossref_primary_10_3390_ijms231911086 crossref_primary_10_1016_j_patbio_2014_07_010 crossref_primary_10_1093_carcin_bgt371 crossref_primary_10_1210_en_2007_1045 crossref_primary_10_1007_s00394_018_1753_7 |
Cites_doi | 10.1172/JCI117936 10.1016/S0168-8227(00)00247-3 10.1016/S1369-5274(00)00143-0 10.1074/jbc.274.4.2118 10.1074/jbc.273.29.18623 10.1074/jbc.M414204200 10.1001/jama.286.3.327 10.1172/JCI118504 10.2337/diabetes.52.6.1319 10.1128/MCB.23.6.2068-2082.2003 10.1038/35078107 10.1007/BF00400597 10.1073/pnas.0507660103 10.1007/s00125-004-1428-1 10.1016/j.cell.2006.03.048 10.2337/diabetes.52.7.1799 10.1074/jbc.C300542200 10.1007/BF00401208 10.1016/j.cmet.2005.09.005 10.2337/diabetes.54.10.2939 10.1016/j.cmet.2006.04.008 10.2337/diabetes.51.5.1596 10.2337/diab.41.2.S97 10.1016/j.imlet.2004.08.004 10.1073/pnas.0600040103 |
ContentType | Journal Article |
Copyright | 2007 © 2007 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. |
Copyright_xml | – notice: 2007 © 2007 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TM 8FD FR3 P64 RC3 7X8 ADTPV AOWAS D8T ZZAVC |
DOI | 10.1074/jbc.M608602200 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nucleic Acids Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Engineering Research Database Technology Research Database Nucleic Acids Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1083-351X |
EndPage | 7789 |
ExternalDocumentID | oai_swepub_ki_se_572101 17227768 10_1074_jbc_M608602200 S0021925820637838 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -DZ -ET -~X .55 0SF 186 18M 2WC 34G 39C 4.4 53G 5BI 5GY 5RE 5VS 6I. 79B 85S AAEDW AAFTH AAFWJ AARDX AAXUO ABDNZ ABOCM ABPPZ ABRJW ACGFO ACNCT ADBBV ADIYS ADNWM AENEX AEXQZ AFFNX AFMIJ AFOSN AFPKN AI. ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BTFSW C1A CJ0 CS3 DIK DU5 E3Z EBS EJD F20 F5P FDB FRP GROUPED_DOAJ GX1 HH5 HYE IH2 KQ8 L7B MVM N9A OHT OK1 P-O P0W P2P R.V RHF RHI RNS ROL RPM SJN TBC TN5 TR2 UHB UKR UPT UQL VH1 VQA W8F WH7 WHG WOQ X7M XFK XSW Y6R YQT YSK YWH YZZ ZA5 ZE2 ~02 ~KM .7T .GJ 0R~ 29J 3O- 41~ 6TJ AALRI AAYJJ AAYOK AAYWO AAYXX ABFSI ACSFO ACVFH ACYGS ADCNI ADVLN ADXHL AEUPX AFPUW AIGII AITUG AKBMS AKRWK AKYEP BAWUL CITATION E.L FA8 H13 J5H NHB QZG XJT YYP ZGI ZY4 CGR CUY CVF ECM EIF NPM PKN Z5M 7TM 8FD FR3 P64 RC3 7X8 ADTPV AOWAS D8T ZZAVC |
ID | FETCH-LOGICAL-c451t-cca582bc60fb8de836708db998c2727b868d809017fbdec57c15933a6a3784d63 |
ISSN | 0021-9258 |
IngestDate | Mon Sep 01 03:34:39 EDT 2025 Thu Sep 04 19:09:14 EDT 2025 Fri Sep 05 03:00:37 EDT 2025 Wed Feb 19 02:29:11 EST 2025 Tue Jul 01 02:13:13 EDT 2025 Thu Apr 24 23:02:53 EDT 2025 Fri Feb 23 02:47:14 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
License | This is an open access article under the CC BY license. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c451t-cca582bc60fb8de836708db998c2727b868d809017fbdec57c15933a6a3784d63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:12133354 |
PMID | 17227768 |
PQID | 19849723 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | swepub_primary_oai_swepub_ki_se_572101 proquest_miscellaneous_70252491 proquest_miscellaneous_19849723 pubmed_primary_17227768 crossref_citationtrail_10_1074_jbc_M608602200 crossref_primary_10_1074_jbc_M608602200 elsevier_sciencedirect_doi_10_1074_jbc_M608602200 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-03-16 |
PublicationDateYYYYMMDD | 2007-03-16 |
PublicationDate_xml | – month: 03 year: 2007 text: 2007-03-16 day: 16 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of biological chemistry |
PublicationTitleAlternate | J Biol Chem |
PublicationYear | 2007 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Duncan, Schmidt, Pankow, Ballantyne, Couper, Vigo, Hoogeveen, Folsom, Heiss (bib5) 2003; 52 Hotamisligil, Arner, Caro, Atkinson, Spiegelman (bib6) 1995; 95 Freeman, Norrie, Caslake, Gaw, Ford, Lowe, O'Reilly, Packard, Sattar (bib4) 2002; 51 Plomgaard, Bouzakri, Krogh-Madsen, Mittendorfer, Zierath, Pedersen (bib11) 2005; 54 Bouzakri, Roques, Gual, Espinosa, Guebre-Egziabher, Riou, Laville, March, Brustel, Tanti, Vidal (bib20) 2003; 52 Pradhan, Manson, Rifai, Buring, Ridker (bib3) 2001; 286 Machida, Umikawa, Takei, Sakima, Myagmar, Taira, Uezato, Ogawa, Kariya (bib19) 2004; 279 Eguez, Lee, Chavez, Miinea, Kane, Lienhard, McGraw (bib25) 2005; 2 Mishima, Kuyama, Tada, Takahashi, Ishioka, Kibata (bib9) 2001; 52 Bouzakri, Zachrisson, Al-Khalili, Zhang, Koistinen, Krook, Zierath (bib26) 2006; 4 Favata, Horiuchi, Manos, Daulerio, Stradley, Feeser, Van Dyk, Pitts, Earl, Hobbs, Copeland, Magolda, Scherle, Trzaskos (bib23) 1998; 273 Bouzakri, Roques, Debard, Berbe, Rieusset, Laville, Vidal (bib22) 2004; 47 DeFronzo (bib2) 1992; 35 Mack, Von Goetz, Lin, Venegas, Barnhart, Lu, Lamar, Stull, Silvin, Owings, Bih, Abo (bib14) 2005; 96 Yki-Jarvinen (bib1) 1995; 38 Rangaswami, Bulbule, Kundu (bib16) 2005; 280 Yao, Zhou, Wang, Brown, Diener, Gan, Tan (bib12) 1999; 274 Feingold, Grunfeld (bib10) 1992; 41 Tang, Guilherme, Chakladar, Powelka, Konda, Virbasius, Nicoloro, Straubhaar, Czech (bib13) 2006; 103 Elbashir, Harborth, Lendeckel, Yalcin, Weber, Tuschl (bib21) 2001; 411 Wright, Wang, Manning, LaMere, Le, Zhu, Khatry, Flanagan, Buckley, Whyte, Howlett, Bischoff, Lipson, Jallal (bib24) 2003; 23 Collins, Hong, Sapinoso, Zhou, Liu, Micklash, Schultz, Hampton (bib15) 2006; 103 Elion (bib18) 2000; 3 Winkler, Lakatos, Nagy, Speer, Salamon, Szekeres, Kovacs, Cseh (bib8) 1998; 21 Saghizadeh, Ong, Garvey, Henry, Kern (bib7) 1996; 97 Zohn, Li, Skolnik, Anderson, Han, Niswander (bib17) 2006; 125 Tang (10.1074/jbc.M608602200_bib13) 2006; 103 Rangaswami (10.1074/jbc.M608602200_bib16) 2005; 280 Yki-Jarvinen (10.1074/jbc.M608602200_bib1) 1995; 38 Bouzakri (10.1074/jbc.M608602200_bib20) 2003; 52 Mack (10.1074/jbc.M608602200_bib14) 2005; 96 Plomgaard (10.1074/jbc.M608602200_bib11) 2005; 54 Freeman (10.1074/jbc.M608602200_bib4) 2002; 51 Eguez (10.1074/jbc.M608602200_bib25) 2005; 2 Bouzakri (10.1074/jbc.M608602200_bib26) 2006; 4 Zohn (10.1074/jbc.M608602200_bib17) 2006; 125 Yao (10.1074/jbc.M608602200_bib12) 1999; 274 Hotamisligil (10.1074/jbc.M608602200_bib6) 1995; 95 Feingold (10.1074/jbc.M608602200_bib10) 1992; 41 Elion (10.1074/jbc.M608602200_bib18) 2000; 3 Collins (10.1074/jbc.M608602200_bib15) 2006; 103 Saghizadeh (10.1074/jbc.M608602200_bib7) 1996; 97 Elbashir (10.1074/jbc.M608602200_bib21) 2001; 411 Duncan (10.1074/jbc.M608602200_bib5) 2003; 52 Wright (10.1074/jbc.M608602200_bib24) 2003; 23 Bouzakri (10.1074/jbc.M608602200_bib22) 2004; 47 Mishima (10.1074/jbc.M608602200_bib9) 2001; 52 Favata (10.1074/jbc.M608602200_bib23) 1998; 273 DeFronzo (10.1074/jbc.M608602200_bib2) 1992; 35 Pradhan (10.1074/jbc.M608602200_bib3) 2001; 286 Machida (10.1074/jbc.M608602200_bib19) 2004; 279 Winkler (10.1074/jbc.M608602200_bib8) 1998; 21 |
References_xml | – volume: 274 start-page: 2118 year: 1999 end-page: 2125 ident: bib12 publication-title: J. Biol. Chem. – volume: 125 start-page: 957 year: 2006 end-page: 969 ident: bib17 publication-title: Cell – volume: 21 start-page: 1778 year: 1998 end-page: 1779 ident: bib8 publication-title: Diabetes Care – volume: 280 start-page: 19381 year: 2005 end-page: 19392 ident: bib16 publication-title: J. Biol. Chem. – volume: 52 start-page: 119 year: 2001 end-page: 123 ident: bib9 publication-title: Diabetes Res. Clin. Pract. – volume: 279 start-page: 15711 year: 2004 end-page: 15714 ident: bib19 publication-title: J. Biol. Chem. – volume: 51 start-page: 1596 year: 2002 end-page: 1600 ident: bib4 publication-title: Diabetes – volume: 3 start-page: 573 year: 2000 end-page: 581 ident: bib18 publication-title: Curr. Opin. Microbiol. – volume: 41 start-page: 97 year: 1992 end-page: 101 ident: bib10 publication-title: Diabetes – volume: 38 start-page: 1378 year: 1995 end-page: 1388 ident: bib1 publication-title: Diabetologia – volume: 96 start-page: 129 year: 2005 end-page: 145 ident: bib14 publication-title: Immunol. Lett. – volume: 47 start-page: 1314 year: 2004 end-page: 1323 ident: bib22 publication-title: Diabetologia – volume: 273 start-page: 18623 year: 1998 end-page: 18632 ident: bib23 publication-title: J. Biol. Chem. – volume: 103 start-page: 2087 year: 2006 end-page: 2092 ident: bib13 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 35 start-page: 389 year: 1992 end-page: 397 ident: bib2 publication-title: Diabetologia – volume: 52 start-page: 1319 year: 2003 end-page: 1325 ident: bib20 publication-title: Diabetes – volume: 52 start-page: 1799 year: 2003 end-page: 1805 ident: bib5 publication-title: Diabetes – volume: 23 start-page: 2068 year: 2003 end-page: 2082 ident: bib24 publication-title: Mol. Cell Biol. – volume: 97 start-page: 1111 year: 1996 end-page: 1116 ident: bib7 publication-title: J. Clin. Investig. – volume: 103 start-page: 3775 year: 2006 end-page: 3780 ident: bib15 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 286 start-page: 327 year: 2001 end-page: 334 ident: bib3 publication-title: J. Am. Med. Assoc. – volume: 95 start-page: 2409 year: 1995 end-page: 2415 ident: bib6 publication-title: J. Clin. Investig. – volume: 411 start-page: 494 year: 2001 end-page: 498 ident: bib21 publication-title: Nature – volume: 4 start-page: 89 year: 2006 end-page: 96 ident: bib26 publication-title: Cell Metab. – volume: 54 start-page: 2939 year: 2005 end-page: 2945 ident: bib11 publication-title: Diabetes – volume: 2 start-page: 263 year: 2005 end-page: 272 ident: bib25 publication-title: Cell Metab. – volume: 95 start-page: 2409 year: 1995 ident: 10.1074/jbc.M608602200_bib6 publication-title: J. Clin. Investig. doi: 10.1172/JCI117936 – volume: 52 start-page: 119 year: 2001 ident: 10.1074/jbc.M608602200_bib9 publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/S0168-8227(00)00247-3 – volume: 3 start-page: 573 year: 2000 ident: 10.1074/jbc.M608602200_bib18 publication-title: Curr. Opin. Microbiol. doi: 10.1016/S1369-5274(00)00143-0 – volume: 274 start-page: 2118 year: 1999 ident: 10.1074/jbc.M608602200_bib12 publication-title: J. Biol. Chem. doi: 10.1074/jbc.274.4.2118 – volume: 273 start-page: 18623 year: 1998 ident: 10.1074/jbc.M608602200_bib23 publication-title: J. Biol. Chem. doi: 10.1074/jbc.273.29.18623 – volume: 21 start-page: 1778 year: 1998 ident: 10.1074/jbc.M608602200_bib8 publication-title: Diabetes Care – volume: 280 start-page: 19381 year: 2005 ident: 10.1074/jbc.M608602200_bib16 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M414204200 – volume: 286 start-page: 327 year: 2001 ident: 10.1074/jbc.M608602200_bib3 publication-title: J. Am. Med. Assoc. doi: 10.1001/jama.286.3.327 – volume: 97 start-page: 1111 year: 1996 ident: 10.1074/jbc.M608602200_bib7 publication-title: J. Clin. Investig. doi: 10.1172/JCI118504 – volume: 52 start-page: 1319 year: 2003 ident: 10.1074/jbc.M608602200_bib20 publication-title: Diabetes doi: 10.2337/diabetes.52.6.1319 – volume: 23 start-page: 2068 year: 2003 ident: 10.1074/jbc.M608602200_bib24 publication-title: Mol. Cell Biol. doi: 10.1128/MCB.23.6.2068-2082.2003 – volume: 411 start-page: 494 year: 2001 ident: 10.1074/jbc.M608602200_bib21 publication-title: Nature doi: 10.1038/35078107 – volume: 38 start-page: 1378 year: 1995 ident: 10.1074/jbc.M608602200_bib1 publication-title: Diabetologia doi: 10.1007/BF00400597 – volume: 103 start-page: 2087 year: 2006 ident: 10.1074/jbc.M608602200_bib13 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0507660103 – volume: 47 start-page: 1314 year: 2004 ident: 10.1074/jbc.M608602200_bib22 publication-title: Diabetologia doi: 10.1007/s00125-004-1428-1 – volume: 125 start-page: 957 year: 2006 ident: 10.1074/jbc.M608602200_bib17 publication-title: Cell doi: 10.1016/j.cell.2006.03.048 – volume: 52 start-page: 1799 year: 2003 ident: 10.1074/jbc.M608602200_bib5 publication-title: Diabetes doi: 10.2337/diabetes.52.7.1799 – volume: 279 start-page: 15711 year: 2004 ident: 10.1074/jbc.M608602200_bib19 publication-title: J. Biol. Chem. doi: 10.1074/jbc.C300542200 – volume: 35 start-page: 389 year: 1992 ident: 10.1074/jbc.M608602200_bib2 publication-title: Diabetologia doi: 10.1007/BF00401208 – volume: 2 start-page: 263 year: 2005 ident: 10.1074/jbc.M608602200_bib25 publication-title: Cell Metab. doi: 10.1016/j.cmet.2005.09.005 – volume: 54 start-page: 2939 year: 2005 ident: 10.1074/jbc.M608602200_bib11 publication-title: Diabetes doi: 10.2337/diabetes.54.10.2939 – volume: 4 start-page: 89 year: 2006 ident: 10.1074/jbc.M608602200_bib26 publication-title: Cell Metab. doi: 10.1016/j.cmet.2006.04.008 – volume: 51 start-page: 1596 year: 2002 ident: 10.1074/jbc.M608602200_bib4 publication-title: Diabetes doi: 10.2337/diabetes.51.5.1596 – volume: 41 start-page: 97 year: 1992 ident: 10.1074/jbc.M608602200_bib10 publication-title: Diabetes doi: 10.2337/diab.41.2.S97 – volume: 96 start-page: 129 year: 2005 ident: 10.1074/jbc.M608602200_bib14 publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2004.08.004 – volume: 103 start-page: 3775 year: 2006 ident: 10.1074/jbc.M608602200_bib15 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0600040103 |
SSID | ssj0000491 |
Score | 2.245221 |
Snippet | Tumor necrosis factor-α (TNF-α) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We tested... Tumor necrosis factor-alpha (TNF-alpha) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We... Tumor necrosis factor- alpha (TNF- alpha ) induces skeletal muscle insulin resistance by impairing insulin signaling events involved in GLUT4 translocation. We... |
SourceID | swepub proquest pubmed crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 7783 |
SubjectTerms | Cell Differentiation Deoxyglucose - metabolism Gene Silencing Humans Insulin Resistance Interleukin-6 - metabolism Intracellular Signaling Peptides and Proteins Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Muscle Fibers, Skeletal - metabolism Muscle, Skeletal - metabolism Phosphorylation Protein-Serine-Threonine Kinases - genetics Protein-Serine-Threonine Kinases - metabolism Signal Transduction Tumor Necrosis Factor-alpha - metabolism |
Title | MAP4K4 Gene Silencing in Human Skeletal Muscle Prevents Tumor Necrosis Factor-α-induced Insulin Resistance |
URI | https://dx.doi.org/10.1074/jbc.M608602200 https://www.ncbi.nlm.nih.gov/pubmed/17227768 https://www.proquest.com/docview/19849723 https://www.proquest.com/docview/70252491 http://kipublications.ki.se/Default.aspx?queryparsed=id:12133354 |
Volume | 282 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXa9NBeijbp4nTjoUgPgVKLpkTqaAQJgjpOF9iAb4Qo0YjrWgoiqUDz9R1ukrMYXS6CTGuD5ol8Q868Qeh9BmOmHCRzcHJSHtBYJkEaSRJoKRRGo0iFZkJ_fBafTOmnWTTrCl2a7JJaHmRXd-aV_I9VoQ3sqrNk_8Gy7UWhAfbBvrAFC8P2r2w8Hn6hI6qrIKv9aqHTh1yGiq28Vy1hTNHJjqumgjO1HsBPk9BWN6vycr9QeohcVK7mTmDSbgPw0RsdE-CD1MEd1xTTY-N7h641LmulnKzYiK8g1zr6ZXOVLm1C-wg881U7V73Qgs7nLktbB4t9uzYHwXQQlk2RbHMCwiAhVoTd96uEk3UAhWvdJGO2es2t_hsIje6_ZXYwjvu6PJbVMb0hlH32WRxPT0_F5Gg2uY8eEMbMCv3oaycUD46PLZboHszrdTL68frVN_GR2_7GDTFZQ0AmT9Bj97bx0MLgKbqnim20MyzSulz9wnvYxPKaRZJt9PDQW2EHFRYlWKMEtyjBiwIblGCPEmxRgj1KsEEJ9ijBd6EEO5TgDiXP0PT4aHJ4ErgqG0FGo7AO4BOOOJFZ3J9LniuuFf14LsENzwiQW8ljnvM-0EY2l7nKIpYBAx4M0jgdME7zePAcbRVloV4inLAkzCX08gkPaaqyZA4_SEgVkFgJRLuHAv-uReYk6HUllB_ChEIwKsA2orNND31oj7-w4isbjwy96YSjjpYSCkDWxnPeeRsLMIleKEsLVTaVCBNOdTW-zUcwcBUIQKyHXlhwdM_HCOAx5j20Z9HS_qOF3F3TEvaUiBiBAXH3jzd5hR51H91rtFVfNuoNUOFavjWg_w1LoLee |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MAP4K4+gene+silencing+in+human+skeletal+muscle+prevents+tumor+necrosis+factor-alpha-induced+insulin+resistance&rft.jtitle=The+Journal+of+biological+chemistry&rft.au=Bouzakri%2C+Karim&rft.au=Zierath%2C+Juleen+R&rft.date=2007-03-16&rft.issn=0021-9258&rft.volume=282&rft.issue=11&rft.spage=7783&rft_id=info:doi/10.1074%2Fjbc.M608602200&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9258&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9258&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9258&client=summon |